Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zongertinib - Boehringer Ingelheim

Next Previous
Drug Profile

Zongertinib - Boehringer Ingelheim

Alternative Names: BI 1810631; Hernexeos

Latest Information Update: 05 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amides; Antineoplastics; Benzimidazoles; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I/II Adenocarcinoma; HER2 positive breast cancer

Most Recent Events

  • 20 Apr 2026 Boehringer Ingelheim plans a phase I pharmacokinetics trial in Healthy volunteers in Germany (PO), in June 2026 (CTIS2025-523193-16-00)
  • 16 Apr 2026 Updated efficacy and adverse event data from a phase I Beamion LUNG-1 trial in Non-small cell lung cancer released by Boehringer Ingelheim
  • 23 Mar 2026 Boehringer Ingelheim plans a phase II Beamion 44 trial for Non-small cell lung cancer (First line therapy, Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable) in Australia, China, France, Germany, Japan, South Korea, Spain in May 2026 (NCT07486817)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top